机器人辅助根治性前列腺切除术中神经血管结构邻近冰冻切片检查(NeuroSAFE)的系统综述与比较研究Meta分析
该系统综述与Meta分析比较了NeuroSAFE引导的机器人辅助根治性前列腺切除术(RARP)与单纯RARP的手术、病理和功能结局。共纳入7项研究(1项随机临床试验、1项前瞻性非随机试验、5项回顾性研究),4,207例患者中2,247例(53%)接受NeuroSAFE引导RARP,1,960例(47%)接受单纯RARP。结果显示NeuroSAFE增加神经保留RARP的可能性(OR 5.49,95% CI 2.48-12.12,I²=72%),降低最终病理切缘阳性(OR 0.55,95% CI 0.39-0.79,I²=73%)和生化复发风险(OR 0.47,95% CI 0.35-0.62,I²=0%),并提高术后12个月无尿垫(OR 2.01,95% CI 1.25-3.25,I²=0%)和勃起功能恢复(OR 3.50,95% CI 2.34-5.23,I²=0%)的可能性。
要点
- NeuroSAFE引导RARP较单纯RARP增加神经保留手术可能性(OR 5.49,95% CI 2.48-12.12)。
- NeuroSAFE降低最终病理切缘阳性(OR 0.55,95% CI 0.39-0.79)和生化复发风险(OR 0.47,95% CI 0.35-0.62)。
- 术后12个月,NeuroSAFE组无尿垫(OR 2.01,95% CI 1.25-3.25)和勃起功能恢复(OR 3.50,95% CI 2.34-5.23)可能性更高。
核心结论
- 现有证据提示NeuroSAFE可能代表一种基于组织学的神经血管束保留方法,拓宽神经保留RARP的适应证,降低切缘阳性和后续生化复发的可能性,并可能转化为更好的术后功能结局。
- 然而当前证据主要来自非随机研究,偏倚风险高。
研究设计与样本
- 系统综述与Meta分析,检索PubMed®、Scopus®和Web of Science™(2024年2月),纳入回顾性和/或前瞻性比较研究。
- 共纳入7项研究(1项随机临床试验、1项前瞻性非随机试验、5项回顾性研究),总计4,207例患者。
- NeuroSAFE组2,247例(53%),单纯RARP组1,960例(47%)。
- 连续变量采用加权均数差(WMD),二分类变量采用比值比(OR)分析。
主要发现
- NeuroSAFE增加神经保留RARP的可能性(OR 5.49,95% CI 2.48-12.12,I²=72%)。
- NeuroSAFE组最终病理切缘阳性可能性降低(OR 0.55,95% CI 0.39-0.79,I²=73%)。
- NeuroSAFE组生化复发可能性降低(OR 0.47,95% CI 0.35-0.62,I²=0%)。
- 术后12个月,NeuroSAFE组无尿垫可能性更高(OR 2.01,95% CI 1.25-3.25,I²=0%)。
- 术后12个月,NeuroSAFE组勃起功能恢复可能性更高(OR 3.50,95% CI 2.34-5.23,I²=0%)。
局限性
- 当前证据主要来自非随机研究,偏倚风险高。
- 神经保留RARP的合并分析异质性I²=72%。
- 切缘阳性的合并分析异质性I²=73%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare surgical, pathological, and functional outcomes of patients undergoing NeuroSAFE-guided RARP vs. RARP alone. METHODS: In February 2024, a literature search and assessment was conducted through PubMed®, Scopus®, and Web of Science™, to retrieve data of men with PCa (P) undergoing RARP with NeuroSAFE (I) versus RARP without NeuroSAFE (C) to evaluate surgical, pathological, oncological, and functional outcomes (O), across retrospective and/or prospective comparative studies (Studies). Surgical (operative time [OT], number of nerve-sparing [NS] RARP, number of secondary resections after NeuroSAFE), pathological (PSM), oncological (biochemical recurrence [BCR]), and functional (postoperative continence and sexual function recovery) outcomes were analyzed, using weighted mean difference (WMD) for continuous variables and odd ratio (OR) for dichotomous variables. RESULTS: Overall, seven studies met the inclusion criteria (one randomized clinical trial, one prospective non-randomized trial and five retrospective studies) and were eligible for SR and MA. A total of 4,207 patients were included in the MA, with 2247 patients (53%) undergoing RARP with the addition of NeuroSAFE, and 1 960 (47%) receiving RARP alone. The addition of NeuroSAFE enhanced the likelihood of receiving a nerve-sparing (NS) RARP (OR 5.49, 95% CI 2.48-12.12, I2 = 72%). In the NeuroSAFE cohort, a statistically significant reduction in the likelihood of PSM at final pathology (OR 0.55, 95% CI 0.39-0.79, I2 = 73%) was observed. Similarly, a reduced likelihood of BCR favoring the NeuroSAFE was obtained (OR 0.47, 95% CI 0.35-0.62, I2 = 0%). At 12-month postoperatively, NeuroSAFE led to a significantly higher likelihood of being pad-free (OR 2.01, 95% CI 1.25-3.25, I2 = 0%), and of erectile function recovery (OR 3.50, 95% CI 2.34-5.23, I2 = 0%). CONCLUSION: Available evidence suggests that NeuroSAFE might represent a histologically based approach to NVB preservation, broadening the indications of NS RARP, reducing the likelihood of PSM and subsequent BCR. In addition, it might translate into better functional postoperative outcomes. However, the current body of evidence is mostly derived from non-randomized studies with a high risk of bias.
引用
- Ditonno F, Bologna E, Licari LC, et al. Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies. Prostate Cancer Prostatic Dis. 2024. PMID: 39232095. doi:10.1038/s41391-024-00891-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。